MarketWatch

Merck dives into COPD treatments with $10 billion purchase of Verona Pharma

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of chronic obstructive pulmonary disease treatments with Verona Pharma’s ...
IEEE

Motion Compensation in Pulmonary Fluorescence Lifetime Imaging: An Image Processing Pipeline for Artefact Reduction and Clinical Precision

Goal: This study introduces Temporal Reliability and Accuracy via Correlation Enhanced Registration (TRACER), a novel image processing pipeline that addresses motion artefacts in real-time ...
Reuters

AstraZeneca drug reduces flare-ups of chronic lung disease in late-stage trials

Rival treatments had mixed results in the past AstraZeneca sees $3-5 billion peak annual sales for its drug Detailed results to be presented at upcoming medical conference Shares among biggest gainers ...
BioPharma Dive

AstraZeneca lung drug gets ‘surprise’ win in COPD trials

AstraZeneca didn’t release complete data from the trials, called Oberon and Titania, stating that they will be disclosed at an upcoming medical meeting. Those details will be closely watched.
Investopedia

How Does Your Income Compare to the Top 10% of America's Wealthiest?

Get personalized, AI-powered answers built on 27+ years of trusted expertise. "Affluent," according to Visa Inc. (V), means being the top 10%. According to the company's November 2025 report, the top ...